(Q37859376)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21449680%20AND%20SRC:MED&resulttype=core&format=json

27 January 2020

title

Sieving treatment biomarkers from blood gene-expression profiles: a pharmacogenomic update on two types of multiple sclerosis therapy (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21449680%20AND%20SRC:MED&resulttype=core&format=json

27 January 2020

0 references

0 references

1 reference

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21449680%20AND%20SRC:MED&resulttype=core&format=json

27 January 2020

author name string

Robert H Goertsches

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21449680%20AND%20SRC:MED&resulttype=core&format=json

27 January 2020

Uwe K Zettl

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21449680%20AND%20SRC:MED&resulttype=core&format=json

27 January 2020

publication date

1 March 2011

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21449680%20AND%20SRC:MED&resulttype=core&format=json

27 January 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21449680%20AND%20SRC:MED&resulttype=core&format=json

27 January 2020

volume

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21449680%20AND%20SRC:MED&resulttype=core&format=json

27 January 2020

issue

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21449680%20AND%20SRC:MED&resulttype=core&format=json

27 January 2020

page(s)

423-432

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21449680%20AND%20SRC:MED&resulttype=core&format=json

Overlapping and distinct mechanisms of action of multiple sclerosis therapies.

27 January 2020

cites work

1 reference

https://api.crossref.org/works/10.2217%2FPGS.10.190

Neuroprotection, regeneration and immunomodulation: broadening the therapeutic repertoire in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.10.190

Predicting responders to therapies for multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.10.190

Current approaches to the identification and management of breakthrough disease in patients with multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.10.190

What do we know about the mechanism of action of disease-modifying treatments in MS?

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.10.190

Interferon-beta mechanisms of action in multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.10.190

The mechanism of action of glatiramer acetate treatment in multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.10.190

United Europeans for development of pharmacogenomics in multiple sclerosis network

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.10.190

Development of biomarkers in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.10.190

Monitoring of multiple sclerosis immunotherapy: from single candidates to biomarker networks.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.10.190

A genomic approach to human autoimmune diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.10.190

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.10.190

Autoimmune T cell responses in the central nervous system

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.10.190

The genetics of multiple sclerosis: SNPs to pathways to pathogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.10.190

Multiple sclerosis: a complicated picture of autoimmunity.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.10.190

Role of the innate immune system in the pathogenesis of multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.10.190

Interleukin-17: a novel inflammatory cytokine that bridges innate and adaptive immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.10.190

Human TH17 lymphocytes promote blood-brain barrier disruption and central nervous system inflammation

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.10.190

MicroRNA miR-326 regulates TH-17 differentiation and is associated with the pathogenesis of multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.10.190

T-helper 17 cells expand in multiple sclerosis and are inhibited by interferon-beta.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.10.190

IFN-beta inhibits human Th17 cell differentiation

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.10.190

T helper type 1 and 17 cells determine efficacy of interferon-beta in multiple sclerosis and experimental encephalomyelitis

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.10.190

Pharmacogenetics of glatiramer acetate therapy for multiple sclerosis reveals drug-response markers.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.10.190

Genome-wide pharmacogenomic analysis of the response to interferon beta therapy in multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.10.190

Genetic polymorphisms, their allele combinations and IFN-beta treatment response in Irish multiple sclerosis patients

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.10.190

ABC-transporter gene-polymorphisms are potential pharmacogenetic markers for mitoxantrone response in multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.10.190

Genome-wide scan of 500,000 single-nucleotide polymorphisms among responders and nonresponders to interferon beta therapy in multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.10.190

Pharmacogenomics of interferon-beta therapy in multiple sclerosis: baseline IFN signature determines pharmacological differences between patients

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.10.190

Molecular profiling of glatiramer acetate early treatment effects in multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.10.190

Long-term genome-wide blood RNA expression profiles yield novel molecular response candidates for IFN-beta-1b treatment in relapsing remitting MS.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.10.190

Transcription-based prediction of response to IFNbeta using supervised computational methods

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.10.190

Zinc-ion binding and cytokine activity regulation pathways predicts outcome in relapsing-remitting multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.10.190

Genomic effects of once-weekly, intramuscular interferon-beta1a treatment after the first dose and on chronic dosing: Relationships to 5-year clinical outcomes in multiple sclerosis patients

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.10.190

Prediction of acute multiple sclerosis relapses by transcription levels of peripheral blood cells

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.10.190

A type I interferon signature in monocytes is associated with poor response to interferon-beta in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.10.190

Clinical trials of multiple sclerosis therapies: improvements to demonstrate long-term patient benefit

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.10.190

Cross-sectional study assessing long-term safety of interferon-beta-1b for relapsing-remitting MS.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.10.190

Clinical effect of neutralizing antibodies to interferon beta that persist long after cessation of therapy for multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.10.190

A brief history of T(H)17, the first major revision in the T(H)1/T(H)2 hypothesis of T cell-mediated tissue damage

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.10.190

The blood-brain barrier, chemokines and multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.10.190

A comparison of the biologic activity of two recombinant IFN-beta preparations used in the treatment of relapsing-remitting multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.10.190

Interferon-beta: mechanism of action and dosing issues

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.10.190

Biological responsiveness to first injections of interferon-beta in patients with multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.10.190

IFN-beta1b induces transient and variable gene expression in relapsing-remitting multiple sclerosis patients independent of neutralizing antibodies or changes in IFN receptor RNA expression.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.10.190

Biological markers of interferon-beta therapy: comparison among interferon-stimulated genes MxA, TRAIL and XAF-1.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.10.190

Type II monocytes modulate T cell-mediated central nervous system autoimmune disease

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.10.190

Interferons at age 50: past, current and future impact on biomedicine

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.10.190

Identification of new sensitive biomarkers for the in vivo response to interferon-beta treatment in multiple sclerosis using DNA-array evaluation.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.10.190

Absence of MxA induction by interferon beta in patients with MS reflects complete loss of bioactivity

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.10.190

Complex immunomodulatory effects of interferon-beta in multiple sclerosis include the upregulation of T helper 1-associated marker genes.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.10.190

Microarray detection of E2F pathway activation and other targets in multiple sclerosis peripheral blood mononuclear cells

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.10.190

Gelatinase B/matrix metalloproteinase-9 cleaves interferon-beta and is a target for immunotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.10.190

Cerebrospinal fluid and serum levels and intrathecal production of active matrix metalloproteinase-9 (MMP-9) as markers of disease activity in patients with multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.10.190

Longitudinal system-based analysis of transcriptional responses to type I interferons

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.10.190

Glatiramer acetate (Copaxone) induces degenerate, Th2-polarized immune responses in patients with multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.10.190

Systems biology and its application to the understanding of neurological diseases.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.10.190

Genome-wide network analysis reveals the global properties of IFN-beta immediate transcriptional effects in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.10.190

A network analysis of the human T-cell activation gene network identifies JAGGED1 as a therapeutic target for autoimmune diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.10.190

A global view of gene activity and alternative splicing by deep sequencing of the human transcriptome

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.10.190

Pharmacogenomics of IFN-beta in multiple sclerosis: towards a personalized medicine approach

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.10.190

Novel approaches to detect serum biomarkers for clinical response to interferon-beta treatment in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.10.190

Genomic effects of IFN-beta in multiple sclerosis patients

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.10.190

Dynamics of interferon-beta modulated mRNA biomarkers in multiple sclerosis patients with anti-interferon-beta neutralizing antibodies.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.10.190

Disease protection and interleukin-10 induction by endogenous interferon-β in multiple sclerosis?

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.10.190

Gene expression analysis of interferon-beta treatment in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.10.190

Microarray analysis identifies interferon beta-regulated genes in multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.10.190

Expression profiling identifies responder and non-responder phenotypes to interferon-beta in multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.10.190

Gene expression profiles reveal homeostatic dynamics during interferon-beta therapy in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.10.190

21 January 2018

Identifiers

DOI

10.2217/PGS.10.190

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21449680%20AND%20SRC:MED&resulttype=core&format=json

27 January 2020

1 reference